 LAUSANNE, Switzerland--BUSINESS WIRE--ADC Therapeutics SA NYSE: ADCT, a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates ADCs for patients with hematologic malignancies and solid tumors, announced today that Jay Feingold, MD, PhD, Senior Vice President and Chief Medical Officer, will depart the company to pursue a new opportunity. ADCT is pleased to announce that Joseph Camardo, MD, will be a 